Prediction markets are pricing a roughly one-in-three chance that Eli Lilly's retatrutide—a triple agonist under development for obesity, diabetes, and fatty liver disease—will secure FDA approval by year-end 2026. The modest probability reflects...
Prediction markets assign xAI only a 1.6% probability of owning the highest-scoring model on Chatbot...
Prediction markets assign just a 1.2% probability to 2026 ranking as the fifth-hottest year on recor...
A prediction market assessing whether US officials will confirm extraterrestrial life exists by end-...
Prediction market odds for DeepSeek's next major AI model release by mid-April 2026 fell sharply fro...
Prediction markets are pricing only a 5.6% chance that SpaceX's Doge-1 CubeSat will launch by the en...
